Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $3.43 billion. The enterprise value is $2.92 billion.
| Market Cap | 3.43B |
| Enterprise Value | 2.92B |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, after market close.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 77.93 million shares outstanding. The number of shares has increased by 11.71% in one year.
| Shares Outstanding | 77.93M |
| Shares Change (YoY) | +11.71% |
| Shares Change (QoQ) | +18.43% |
| Owned by Insiders (%) | 1.94% |
| Owned by Institutions (%) | 97.13% |
| Float | 64.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 855.03 |
| Forward PS | 1,576.85 |
| PB Ratio | 6.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 728.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.07, with a Debt / Equity ratio of 0.10.
| Current Ratio | 13.07 |
| Quick Ratio | n/a |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.90% and return on invested capital (ROIC) is -37.68%.
| Return on Equity (ROE) | -52.90% |
| Return on Assets (ROA) | -45.50% |
| Return on Capital (ROIC) | -37.68% |
| Revenue Per Employee | $13,838 |
| Profits Per Employee | -$739,755 |
| Employee Count | 290 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.61% in the last 52 weeks. The beta is 0.62, so CRNX's price volatility has been lower than the market average.
| Beta (1Y) | 0.62 |
| 52-Week Price Change | +132.61% |
| 50-Day Moving Average | 42.48 |
| 200-Day Moving Average | 31.58 |
| Relative Strength Index (RSI) | 50.67 |
| Average Volume (30 Days) | 807,070 |
Short Selling Information
The latest short interest is 4.91 million, so 6.30% of the outstanding shares have been sold short.
| Short Interest | 4.91M |
| Short Previous Month | 5.01M |
| Short % of Shares Out | 6.30% |
| Short % of Float | 7.59% |
| Short Ratio (days to cover) | 5.00 |
Income Statement
In the last 12 months, CRNX had revenue of $4.01 million and -$214.53 million in losses. Loss per share was -$3.69.
| Revenue | 4.01M |
| Gross Profit | 4.01M |
| Operating Income | -222.61M |
| Pretax Income | -214.53M |
| Net Income | -214.53M |
| EBITDA | -212.22M |
| EBIT | -214.53M |
| Loss Per Share | -$3.69 |
Balance Sheet
The company has $559.86 million in cash and $51.73 million in debt, giving a net cash position of $508.13 million or $6.52 per share.
| Cash & Cash Equivalents | 559.86M |
| Total Debt | 51.73M |
| Net Cash | 508.13M |
| Net Cash Per Share | $6.52 |
| Equity / Book Value | 539.11M |
| Book Value Per Share | 6.92 |
| Working Capital | 530.21M |
Cash Flow
In the last 12 months, operating cash flow was -$166.31 million and capital expenditures -$4.69 million, giving a free cash flow of -$171.00 million.
| Operating Cash Flow | -166.31M |
| Capital Expenditures | -4.69M |
| Free Cash Flow | -171.00M |
| FCF Per Share | -$2.95 |
Margins
Gross margin is 100.00%, with operating and profit margins of -5,547.17% and -5,345.85%.
| Gross Margin | 100.00% |
| Operating Margin | -5,547.17% |
| Pretax Margin | -5,345.85% |
| Profit Margin | -5,345.85% |
| EBITDA Margin | -5,288.34% |
| EBIT Margin | -5,345.85% |
| FCF Margin | -4,261.03% |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.71% |
| Shareholder Yield | -11.71% |
| Earnings Yield | -6.25% |
| FCF Yield | -4.98% |
Analyst Forecast
The average price target for CRNX is $56.25, which is 27.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $56.25 |
| Price Target Difference | 27.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 195.90% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 19.84 and a Piotroski F-Score of 2.
| Altman Z-Score | 19.84 |
| Piotroski F-Score | 2 |